8+ portfolio cos, strong outcome metricsexternal
$210B market, 12% annual growthexternal
Founder is cancer survivor — deep convictionexternal
Portfolio NPS 100, 95% ER deflection rateexternal
Concr: survival 1.5yr → 9.7yr medianexternal
Risa saves $2M/yr per cancer centerexternal
Ignite: 70hrs saved, 90% fewer lab queriesexternal
Tono: 15,000 patients kept on treatmentexternal
mPATH bridges lung screening access gapsexternal
SpotDoc: caught melanoma doctor nearly missedexternal
Gabbi: genetic risk flagged, screening 6-monthlyexternal
Risa freed 36 FTE equiv. at one centerexternal
OncoveryCare: PHQ score 15→2 in one patientexternal
Lumonus: 100 NPS, cuts admin turnaround timeexternal
Reimagine: 95% symptom issues resolved without ERexternal
1,700 US cancer deaths daily, 1,000+ avoidableexternal
Concr Farrsight: 44 lives saved, retrospective studywebsite
90% Americans miss lung cancer screeningwebsite
Ben: 9-month diagnostic journey before Stage IIIA catchwebsite
Early detection + guideline care = infrastructure focuswebsite
Commercially-validated startups only — real-world proof requiredwebsite
Ben collapsed mid-treatment, fought through brutal recoverywebsite
Outdated workflows, misaligned incentives drove fund creationwebsite
90% radiation oncologists report staff shortageswebsite
